S-rivastigmine-desmethylselegiline | 851086-87-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: S-rivastigmine-desmethylselegiline
• 英文别名: [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-[(2R)-1-phenylpropan-2-yl]-N-prop-2-ynylcarbamate
• CAS: 851086-87-8
• 化学式: C₂₃H₂₈N₂O₂
• 分子量: 364.488
• InChiKey: JOAPBSSQCBUBDI-MOPGFXCFSA-N

物化性质

• 沸点：
  466.0±45.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  三光气 、 3-(1-(S)-(N,N-二甲基氨基)乙基)苯酚 、 R-(-)-N-去甲基塞利吉林 在 N,N-二异丙基乙胺 、 sodium hydride 作用下， 以 二氯甲烷 、 乙腈 、 mineral oil 为溶剂， 反应 60.0h， 以92.3%的产率得到S-rivastigmine-desmethylselegiline
  参考文献：
  名称：

  [EN] STIGMINE CONJUGATES FOR SUBSTANCE USE DISORDERS
  [FR] CONJUGUÉS DE STIGMINE POUR DES TROUBLES DE TOXICOMANIE

  摘要：

  该发明涉及用于治疗或预防物质使用障碍的方法。

  公开号：

  WO2010009316A1

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：CoLucid Pharmaceuticals, Inc.

  公开号：EP2314571A2

  公开（公告）日：2011-04-27

  Carbamoyl esters inhibit cholinesterase activity and upon hydrolysis release a pharmacologically active agent. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl treat for example,a nervous system condition, cholinergie deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent such as acetylcholine.

  氨基甲酰基酯可抑制胆碱酯酶的活性，并在水解后释放出具有药理活性的药剂。氨基甲酰基酯可用于治疗疾病。通过水解氨基甲酰基获得的药理活性剂可治疗神经系统疾病、胆碱酯酶缺乏症以及与乙酰胆碱等药理活性剂缺乏有关的疾病。
• Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents
  申请人：Verheijen C. Jeroen

  公开号：US20070275959A1

  公开（公告）日：2007-11-29

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: Formula (I) wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
• Methods for promoting wakefulness
  申请人：Rupniak Nadia M.J.

  公开号：US20090048229A1

  公开（公告）日：2009-02-19

  The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.
• Stigmine Conjugates for Substance Use Disorders
  申请人：Rupniak Nadia

  公开号：US20110251175A1

  公开（公告）日：2011-10-13

  The invention relates to methods for the treatment or prevention of substance use disorders.
• US7795307B2
  申请人：——

  公开号：US7795307B2

  公开（公告）日：2010-09-14